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Ischemic retinal dystrophies are leading causes of acquired vision loss. Although the dysregulated 
expression of the hypoxia‑responsive VEGF‑A is a major driver of ischemic retinopathies, 
implication of additional VEGF‑family members in their pathogenesis has led to the development 
of multivalent anti‑angiogenic tools. Designed as a decoy receptor for all ligands of VEGFR1 and 
VEGFR2, Aflibercept is a potent anti‑angiogenic agent. Notwithstanding, the molecular mechanisms 
mediating Aflibercept’s efficacy remain only partially understood. Here, we used the oxygen‑induced 
retinopathy (OIR) mouse as a model system of pathological retinal vascularization to investigate the 
transcriptional response of the murine retina to hypoxia and of the OIR retina to Aflibercept. While OIR 
severely impaired transcriptional changes normally ensuing during retinal development, analysis of 
gene expression patterns hinted at alterations in leukocyte recruitment during the recovery phase of 
the OIR protocol. Moreover, the levels of Angiopoietin‑2, a major player in the progression of diabetic 
retinopathy, were elevated in OIR tissues and consistently downregulated by Aflibercept. Notably, GO 
term, KEGG pathway enrichment, and expression dynamics analyses revealed that, beyond regulating 
angiogenic processes, Aflibercept also modulated inflammation and supported synaptic transmission. 
Altogether, our findings delineate novel mechanisms potentially underlying Aflibercept’s efficacy 
against ischemic retinopathies.
Retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR) are prominent microvasculopa-
thies that severely compromise retinal  function1. Representing leading causes of vision loss  worldwide2, retinal 
microvasculopathies are characterised by the emergence of new retinal blood vessels in a process known as 
 neovascularization3. Such vessels, however, are immature and leaky. Consequently, nourishment and oxygena-
tion to retinal cells becomes  deficient4. Together with the accumulation of waste products, the latter ultimately 
leads to retinal malfunction and vision impairment.
The identification of the vascular endothelial growth factor A (VEGF-A) as a hypoxia-responsive driver 
of pathological  angiogenesis5 in the  retina6,7 and in  tumours8 led to the development of multiple pharmaco-
logical compounds for its neutralization. Despite their efficacy in the treatment of  cancer9,10 and neovascular 
 retinopathies11,12, VEGF-A inhibitors exhibited unforeseen side effects and limitations, including toxicity, short 
systemic life-times, and limited diffusion across the  tissue3,11,13. The latter, together with findings suggesting 
that the placental growth factor (PGF)—another member of the VEGF-family—played a major role in driving 
pathological  neovascularization14, boosted interest in the development of multivalent anti-angiogenic  therapies15. 
To simultaneously inhibit both PGF and VEGF-A, the decoy receptor Aflibercept (VEGF-Trap, Eylea; hencefort 
AFL) was created. AFL is a fusion protein formed by the extracellular domains of VEGF receptor 1 (VEGFR1) 
and VEGFR2 joined to the crystallizable fragment of human  IgG16,17. Thereby, AFL is capable of neutralizing 
the ligands of VEGFR1 and  VEGFR218 and has received FDA approval for the treatment of age-related macular 
degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion, and back-
ground  DR2. However, AFL has not yet been authorized for use against PDR (off-label only) or ROP, although 
phase III clinical trials are ongoing for the latter (NCT04004208).
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Previously, we used the oxygen-induced retinopathy (OIR) mouse  model19, which represents the most widely 
studied in vivo model of retinal proliferative microvascular  disease20,21, to investigate the effects of AFL adminis-
tration on the ischemic  retina22. Our study revealed that AFL potently inhibits retinal neovascularization while 
permitting the concomitant revascularization of the tissue and partially protecting dopaminergic amacrine cells 
from hypoxic damage. Additionally, transcriptional profiling during the proliferative phase of the OIR protocol 
(P14 and P17; Fig. 1a, b) revealed that AFL exerts a modulatory effect on the expression of genes associated with 
angiogenesis and  adhesion22. Notwithstanding, the molecular mechanisms supporting the endogenous capacity 
of the murine retina to drive neovascular tuft clearance at later stages remain poorly  understood23. Moreover, the 
transcriptional profile of the ischemic retina in response to AFL during the distinct phases of the OIR protocol has 
not yet been investigated. To address these questions, we extended our transcriptomic analyses to also consider 
a time-point within the phase of neovascular tuft regression (P19) using two distinct AFL treatment regimens (2 
doses vs 3 doses; Fig. 1c). By conducting cross-comparisons between time-points and treatment schedules, our 
results hint at the involvement of leukocytes during the recovery phase of the OIR protocol (in line with recent 
 reports24), and at positive effects of AFL on synaptic transmission in OIR retinas, where its administration seems 
to protect retinal ganglion cells (RGCs) from hypoxic damage.
Results
The OIR protocol profoundly hinders retinal development. The murine retina has been used exten-
sively to study blood vessel formation and endothelial cell (EC) behaviour in health and  disease20. Here, we 
used the mouse model of OIR to investigate the transcriptional changes undergone by retinal cells in response 
to hypoxia and to subsequent anti-angiogenic therapy. To this aim, we administered AFL, a recombinant decoy 
receptor neutralizing the ligands of VEGFR1 and VEGFR2, at a dose of 25 mg/kg body weight to mice subjected 
to the OIR protocol. The drug was injected intra-peritoneally (i.p.) following two distinct regimens: either (1) on 
P13 and P15, or (2) on P13, P15 and P17 (Fig. 1c). At P19, total RNA isolated from whole retinas was analysed 
by Affymetrix microarrays (see “Methods”). Retinas of age-matched mice reared in normoxia and of OIR lit-
termates not injected with AFL were used as controls.
Previously, we described the transcriptional state of the OIR retina at P14 and P17 after AFL  administration22 
(Fig. 1a,b; GEO accession number: GSE 124956). Here, we build on our previous report to dissect the temporal 
dynamics of gene expression in normoxic and OIR retinas and to additionally assess the retinal transcriptional 
state during the recovery phase of the OIR protocol, i.e. at P19, and in response to AFL. First, we addressed 
whether OIR interfered with the transcriptional changes occurring in the course of normal retinal development. 
To this aim, we conducted comparisons between the gene expression profiles of P14, P17 and P19 normoxic 
retinas. The latter revealed moderate changes in transcriptional activity between P14 and P17 (473 differentially 
regulated genes [DRGs]; fold-change above 1.2 and P-value below 0.05), which increased over 2.5 times for the 
period between P17 and P19 (1240 DRGs; Fig. 2a; Supplementary Tables 1–4). Unexpectedly, only 56 DRGs were 
Figure 1.  Schematic representation of AFL treatment regimens. (a) In the first regimen, mice subjected to 
the OIR protocol (75% oxygen concentration from P6 to P11) were treated with AFL (25 mg/kg body weight) 
on P13. Thereafter, on P14, RNA from the retinas of these animals (P14 OIR + AFL) and of non-injected OIR 
controls (P14 OIR) and normoxic controls (P14 Normoxia; not shown) was collected. (b) In a second treatment 
regimen, mice subjected to the OIR protocol were treated with AFL on P13 and P15 and RNA from their retinas 
was isolated on P17 (P17 OIR + AFL). Non-injected age-matched OIR littermates (P17 OIR) and normoxic 
age-matched animals (P17 Normoxia; not shown) were used as controls. (c) Finally, mice subjected to the OIR 
protocol received either 2 or 3 doses of AFL (P19 OIR + AFL (× 2) and P19 OIR + AFL (× 3), respectively) prior 
to RNA collection on P19. Retinas of non-treated age-matched littermates (P19 OIR) and of normoxic age-
matched animals (P19 Normoxia) were used as controls.
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identified in OIR retinas in the period between P14 and P17 (Fig. 2a; Supplementary Tables 5–6). In contrast, 
1367 DRGs were found between P17 and P19 in OIR retinas (Supplementary Tables 7–8), which represents ~ 10% 
more than in normoxic samples during the same time frame (Fig. 2a). Surprisingly, only 2 of the 282 differen-
tially up-regulated genes from P14 to P17 in normoxia (< 1%) were also up-regulated in OIR mice (~ 4%), with 
none of the down-regulated genes being found in both OIR and normoxic retinas during this period (Fig. 2b, 
left). Conversely, ~ 44% (385/873) of the up-regulated genes and ~ 40% (148/367) of the down-regulated genes 
found in normoxic tissues between P17 and P19 were also detected as differentially expressed in OIR retinas 
during this time window (Fig. 2b, right). The latter accounted for ~ 42% and ~ 32.5% of all differentially up- and 
down-regulated genes in OIR retinas, respectively (912 up, 455 down). These observations suggested a delay in 
the maturation process of the retinal tissue as a consequence of the OIR protocol. In this context, gene ontology 
(GO) term enrichment analysis (Fig. 2c, top)25–27 using genes differentially expressed in normoxic retinas at P17 
relative to P14 identified terms associated to retinal development and visual perception (e.g. visual perception, 
sensory organ development), potentially supported by enhanced ion transport (e.g. potassium ion transport), 
and neuronal and synaptic maturation (e.g. chemical synaptic transmission, neuron development). In contrast, 
GO terms enriched in OIR retinas at P17 relative to P14 were primarily associated to injury repair (e.g. wound 
healing), inflammation (e.g. response to interferon-gamma), hypoxia (peptidyl-proline hydroxylation to 4-hydroxy-
L-proline), and angiogenesis (e.g. positive regulation of cell migration involved in sprouting angiogenesis). In line 
with these findings, a recent study reported that sterile inflammation and the recruitment of neutrophils are 
both essential for the clearance of neovascular tufts from the OIR  retina24. Meanwhile, GO terms enriched at 
P19 compared to P17 were mainly related to metabolic changes in both normoxic and OIR retinas (Fig. 2c, bot-
tom). An unexpected finding at first sight was the enrichment of the GO term “response to ischemia” in the set 
of DRGs identified in normoxic retinas from P14 to P17 (Fig. 2a). Nonetheless, moderate hypoxia is known to 
be required for retinal development and  vascularization28. Among the genes associated to this GO term, Egr1 
encodes the Early growth response 1 transcription factor, which regulates the expression of multiple genes, 
including the Hypoxia inducible factor 1 subunit alpha (HIF-1α)29.
To complement our GO term enrichment analysis, we conducted KEGG pathway enrichment analyses. 
Focusing solely on up-regulated genes, we identified KEGG pathways associated to synaptic maturation (e.g. 
glutamatergic synapse) as enriched from P14 to P17 in normoxic retinas (Fig. 2d, top). In comparison, the KEGG 
pathways enriched during this timeframe in OIR retinas were associated to hypoxia (HIF-1 signaling pathway), 
cancer (e.g. melanoma), response to infection (e.g. staphylococcus aureus infection) and diabetes (AGE-RAGE sig-
nalling pathway in diabetic complications). In agreement with our GO term enrichment analysis, KEGG pathway 
enrichment analysis also revealed that most changes between P17 and P19 were metabolic, both in normoxic 
and OIR retinas (Fig. 2d, bottom). Together, the findings of these analyses suggest that the maturation of retinal 
neurons, occurring during a limited post-natal time window, might be severely impaired in the OIR retina. In 
this context, we have previously shown that the number of dopaminergic amacrine cells is indeed significantly 
reduced as a consequence of the OIR protocol, with numbers failing to reach normoxic levels even in young 
adult  animals22.
Genes associated to angiogenesis, metabolism, and leukocyte migration are regulated in the 
post‑P17 recovery phase of the OIR protocol. Next, we analysed how the transcriptional profiles of 
OIR and normoxic retinas diverged. We identified 272, 662, and 398 DRGs in OIR retinas compared to nor-
moxic controls at P14, P17, and P19, respectively (Fig. 3a; Supplementary Tables 9–14). The latter suggests that 
the transcriptional response of the murine retina to the OIR protocol is most pronounced at P17. Interestingly, 
however, only 14 DRGs were detected in response to OIR at all three time-points (Fig. 3b). Among them, 13 
genes were up-regulated and 1 was down-regulated (Fig. 3c). Most of the up-regulated genes encoded either 
components of the vascular wall (Col4a1, Fn1, Lama4, Mcam, Nid1, Nid2) or proteins relevant for cell-extracel-
lular matrix interactions (Anxa2, Pdlim1). Whereas the synthesis and deposition of basement membrane com-
ponents such as collagen IV (of which a component is encoded by Col4a1) by ECs represent crucial processes in 
blood vessel formation and  maturation30,31, Anxa2 expression is known to be regulated by VEGF and has been 
previously reported to be elevated in OIR retinas, with its knockdown supressing retinal  neovascularization32. 
Further, the up-regulated expression of Angpt2 at all examined time-points might be of key relevance as Angi-
opoietin-2 (Ang2), the protein it encodes, has been detected in high levels in the vitreous of individuals with 
 DR33 and agents for its blockade (e.g. Faricimab) are currently undergoing clinical trials. Additionally, the PDZ 
and LIM domain protein 1 (encoded by Pdlim1) has been recently reported to play a role in the assembly of 
stress fibres and to be potentially involved in cell  migration34, a crucial process for the formation of neovascular 
tufts. While the role of mir-7025 in the context of retinopathy requires investigation, the only gene detected as 
down-regulated in OIR retinas relative to normoxic controls at all three examined time-points was Pcp4. Encod-
ing Purkinje Cell Protein 4, Pcp4 expression has been reported in ganglion, amacrine and horizontal  cells35. 
Thus, our findings hint at a potentially detrimental effect of OIR on these retinal cell populations. Further, the 
expression of the Insulin-like growth factor-binding proteins 5 and 7 (Igfbp5 and Igfbp7) was higher in OIR than 
in normoxic retinas (Fig. 3c). ECs are known to store the protein encoded by Igfbp7, Angiomodulin, together 
with Ang2 and others in Weibel-Palade bodies, storage organelles unique to vascular ECs that deliver mediators 
of inflammation and hemostasis in response to certain  stimuli36. Moreover, Angiomodulin is also a marker of 
cancer vasculature known to be regulated by  VEGF37 and to modulate neoangiogenesis in  response38. In line 
with these reports, elevated mRNA expression of Igfbps, including Igfbp5 and Igfbp7, has been previously found 
in OIR retinas, specifically within neovascular  tufts39. Notwithstanding, the specific function of these molecules 
at this location is unclear and requires further investigation.
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To determine whether gene sets associated to specific cellular functions were differentially expressed in OIR 
retinas relative to normoxic controls, we conducted GO term enrichment analysis at each time-point. Whereas 
the most strongly enriched terms in the molecular function domain at P14 (Fig. 3d, top) were associated to 
metabolism (e.g. 6-phosphofructokinase activity), most were related to the binding of cellular and extracellular 
components (e.g. extracellular matrix binding, integrin binding). At this time-point, GO terms enriched in the 
biological process domain (Fig. 3e, top) were primarily related to angiogenesis (e.g. venous blood vessel develop-
ment). The latter, however, are likely linked to pathological aspects of blood vessel formation as enriched GO 
terms also included the negative regulation of vasoconstriction and the regulation of blood–brain barrier perme-
ability. In agreement, we previously reported hyperpermeability and a higher number of dilated vessels in the 
OIR retina than in normoxic age-matched  controls22. Notably, the GO term “positive regulation of endothelial 
cell chemotaxis by VEGF-activated VEGFR signaling pathway” was also enriched, evidencing the role of VEGF 
in the pathogenesis of OIR.
At P17, GO terms enriched in the molecular function domain (Fig. 3d, middle) were similar to those detected 
at P14, albeit including terms associated to immune cell recruitment (e.g. chemoattractant activity) and VEGF 
signalling (vascular endothelial growth factor receptor binding). GO terms enriched in the biological function 
domain at this time-point also partially overlapped with those detected at P14 (Fig. 3e, middle), and were pri-
marily related to blood vessel formation, vasoconstriction, and vascular permeability. GO terms enriched at 
P17 but not at P14 included “positive regulation of collagen biosynthetic process”, “fibrinolysis” and “synapse 
pruning”. The latter points in the direction of a compromised neuronal network and is in line with our findings 
in the developmental context (Fig. 2).
Although most of the GO terms identified as enriched at P19 within the molecular function domain had 
already been detected at P17, previously unidentified terms included “insulin-like growth factor I binding” and 
“platelet-derived growth factor binding” (Fig. 3d, bottom). Meanwhile, many of the GO terms enriched at P19 
within the biological process domain (Fig. 3e, bottom) were, as observed at P17, related to angiogenesis. Addi-
tionally, resembling the results of our analysis across time-points (Fig. 2), terms associated to inflammation, 
injury response and neuronal development were detected as enriched (e.g. regulation of inflammatory response, 
wound healing, neurogenesis). Remarkably, enriched terms also included some related to leukocyte recruitment 
and to increased apoptosis. These findings are in agreement with previous reports describing a decrease in the 
number of  Foxp3+ Regulatory T cells occurring concomitantly with the emergence of microvascular aberra-
tions in the OIR  retina40, as well as a central role for neutrophils in repairing such aberrations by promoting 
the apoptosis-mediated clearance of senescent ECs within neovascular  tufts24. In particular, 6 genes (Pecam1, 
Ednra, Mstn, Cx3cr1, Mmp14, Nckap1l) belonging to the “positive regulation of leukocyte migration” GO term 
were detected among those differentially up-regulated in P19 OIR retinas relative to age-matched controls. 
Meanwhile, 8 genes belonging to the “leukocyte migration” term were detected, including 5 not associated to 
the term “positive regulation of leukocyte migration”, namely Ccl3, Itgb1, Fcer1g, Cd34 and Itga6. Additionally, 
9 genes were associated to the term “positive regulation of chemotaxis”, including 7 not associated to neither of 
the two previous GO terms: Pdgfrb, Sema7a, Padi2, Angpt2, Tubb2b and Fn1.
Among these genes, Pecam1 is known to be required for leukocyte transendothelial migration under inflam-
matory  conditions41, Mstn was recently shown to be expressed in bloodstream-derived  leukocytes42, and integrin 
β1 (encoded by Itgb1) was recently described to mediate the adhesion of monocytes to liver sinusoidal ECs 
and thereby contribute to hepatic  inflammation43. Further, detecting not only Itgb1 but also Sema7a as up-
regulated is remarkable given that endothelial Semaphorin 7A is known to promote neutrophil migration during 
 hypoxia44 and that vascular Semaphorin 7A up-regulation has been shown to promote atherosclerosis through 
endothelial β1  integrin45. Similarly, monocyte/macrophage-derived matrix metallopeptidase 14 (encoded by 
the Mmp14 gene) has been reported to modulate monocyte infiltration in a context-dependent  manner46 while 
CC chemokine ligand 3 (encoded by Ccl3) is known to induce neutrophil chemotaxis under conditions of acute 
 inflammation47. Meanwhile, knockdown of nckap1l in zebrafish has recently been reported to reduce neutrophil 
 migration48, and its upregulation might thus promote neutrophil recruitment. Hence, an increased presence of 
leukocytes in the OIR retina at P19 is likely. Further, up-regulation of Cx3cr1 might be linked to the significant 
increase in the number of microglial cells previously reported to occur in the OIR  retina49, although it is sur-
prising that the expression of this gene was not up-regulated neither at P17 nor at P14. Considering that Cx3cr1 
Figure 2.  Differential gene expression, GO term enrichment and KEGG Pathway enrichment analyses on 
retinas of normoxic and OIR mice during early post-natal development. (a) Differential gene expression analysis 
of normoxic and OIR retinas across timepoints. The early transcriptional changes that ensue during normal 
retinal post-natal development are hindered when mice are subjected to the OIR protocol (left). In contrast, 
the number of differentially expressed genes between P19 and P17 (right) was higher in OIR retinas than in 
normoxic controls. (b) Venn diagrams of differentially expressed genes in normoxic and OIR retinas on P17 
relative to P14 (left) and on P19 relative to P17 (right). While the overlap in both up- (top) and down-regulated 
genes (bottom) was minimal at the early time frame examined, over 40% of both up- and down-regulated 
genes in normoxic conditions were also detected in OIR retinas at the later time frame investigated. (c) GO 
term enrichment analysis in the Biological process domain was conducted using all differentially regulated 
genes detected in Normoxia (left) and OIR (right) retinas at P17 relative to P14 (top) and at P19 relative to P17 
(bottom). A fraction of the top enriched GO terms and their fold enrichment are depicted for each condition. 
(d) KEGG pathway enrichment analysis was conducted using all differentially up-regulated genes detected 
in Normoxia (left) and OIR (right) retinas at P17 relative to P14 (top) and at P19 relative to P17 (bottom). A 
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depletion has been associated to an accelerated progression of retinopathy in the rat model of streptozotocin-
induced  diabetes50, its up-regulation during the post-P17 phase of the OIR protocol might also play a relevant 
role in recovery. Together, these findings suggest that multiple genes encoding proteins with pronounced, and in 
certain cases complementary, regulatory effects on leukocyte migration are upregulated in the OIR retina at P19.
Genes regulated by AFL are involved in angiogenesis, immune cell recruitment, and neuro-
transmission. To shed light on the transcriptional processes mediating the capacity of anti-angiogenic 
therapy to counteract pathological neovascularization and reduce hypoxia-induced damage in the retina, OIR 
animals were treated with AFL (treatment regimens shown in Fig. 1). AFL administration led to the differential 
regulation of 38 and 149 genes at P14 and P17, respectively (Fig. 4a; Supplementary Tables 15–18). Meanwhile, 
87 and 151 DRGs were detected at P19 in retinas of OIR mice that received AFL on two and three occasions 
(P19 AFLx2 and P19 AFLx3), respectively (Fig. 4a; Supplementary Tables 19–22). Although no single DRG was 
detected in all treatment regimens, 27 genes were differentially regulated at least in two of them, and 5 of these 
in three regimens (Fig. 4b).
Among the DRGs detected in two regimens, those found at P14 and P17 largely overlapped with those that 
we previously  reported22 (Fig. 4c, [i]), confirming that the normalization strategy used for this study did not lead 
to dramatic deviations from our prior findings. Interestingly, while retinas of animals that received two doses of 
AFL expressed lower levels of Lyz2 than those of OIR non-injected littermates at P17, this gene was up-regulated 
at P19 in retinas of mice that followed the same treatment regimen (Fig. 4c, [ii]). Lyz2 has recently been proposed 
as a marker for activated microglia in the context of retinal  degeneration51, with a previous study revealing that 
the activation status of microglial cells is more important than their density in the emergence of OIR-driven 
microvascular  aberrations52. Considering that proangiogenic Lyz2-expressing mononuclear cells are selectively 
recruited to sites of retinal neovascularization in response to VEGF-A and Semaphorin  3A53, we hypothesized 
that the initial reduction and subsequent up-regulation of Lyz2 could potentially reflect the kinetics of VEGF-
A neutralization in animals that received two doses of AFL. However, upon closer inspection, we noticed that 
AFL administration led to an increase in the expression levels of Lyz2 from P14 to P17 which was of the same 
magnitude as that observed in retinas of OIR animals that did not receive AFL during the same period (Supple-
mentary Fig. S1a). In contrast, the expression dynamics of this factor in OIR retinas showed a pronounced peak 
at P17 that by P19 returned to the levels observed at P14. As the levels of this transcript increased progressively 
over-time in retinas of AFL-treated mice, its identification as differentially regulated seems to be mainly a conse-
quence of the marked changes in its expression dynamics in the OIR retina, which might in turn reflect a sharp 
increase in the number of mononuclear cells present in the tissue at P17 as a key step towards neovascular tuft 
 clearance24. In line with this hypothesis, Fam19a4 encodes the Family with sequence similarity 19 (chemokine 
(C–C motif)-like) protein, a secreted molecule that modulates macrophage chemotaxis and  activation54 whose 
expression levels were higher in OIR + AFL than in OIR retinas at P17 but lower in OIR + AFLx3 retinas than in 
OIR(Fig. 4c, [vi]). As in the case of Lyz2, examination of the expression dynamics of Fam19a4 revealed a marked 
capacity of the OIR retina to endogenously regulate the levels of this gene (Supplementary Fig. 1b). Interest-
ingly, Lyz2 expression in normoxic and OIR + AFL retinas followed a similar trend, although its levels remained 
slightly lower in AFL-treated retinas than in controls. Thus, these two genes might serve as important mediators 
of the retinal endogenous capacity to recover from OIR; the molecular machinery regulating their expression 
and function in this context remains to be further investigated.
Unexpectedly, only 11 genes were differentially regulated at P19 in response to both two and three AFL 
doses (Fig. 4b, [iii] and [II]). DRGs detected in only these two conditions (Fig. 4c [iii]) encode an inwardly 
rectifying potassium channel (Kcnj8; Kir6.1 channel), a transcription factor (Sox2), a microRNA (Mirlet7g), the 
Glycosylphosphatidylinositol-anchored molecule-like (Gml), and an uncharacterized protein (Pnmal2). Kcnj8 
mutations have been linked to excessive retinal vessel formation and increased vascular tortuosity in retinas of 
children and adults affected with Cantú syndrome,  respectively55, and Kir6.1 expression has been detected in 
human retinal pigment epithelium (RPE)56. Further, expression of the microRNA (miR) let-7 g is downregulated 
in the heart of mice after coronary occlusion in vivo and in neonatal rat ventricular myocytes subjected to hypoxia 
in vitro, with its ectopic expression preventing hypoxia-dependent caspase activation and death in both  settings57. 
Similarly, hypoxia has been shown to increase the expression of Sox2 in mesenchymal stem  cells58, with higher 
Figure 3.  Differential gene expression and GO term enrichment analyses on retinas of OIR mice relative to 
retinas of normoxic age-matched controls at each of the assessed timepoints. (a) Differential gene expression 
analysis on OIR retinas compared to normoxic age-matched controls across timepoints. Important deviations 
in gene expression profiles are detected, the most prominent of which occurs at P17. (b) Venn diagram of 
differentially expressed genes in OIR retinas relative to normoxic age-matched control samples. Only 14 
transcripts were identified as differentially regulated at all three timepoints. (c) Heatmap depicting the fold-
change expression of the 14 differentially regulated genes identified in (b), of which 13 were up-regulated and 1 
was down-regulated. Noteworthy, the expression levels of up-regulated genes remained high throughout time, 
while the expression of the down-regulated transcript remained low at all timepoints examined. (d) GO term 
enrichment analysis in the Molecular function domain was conducted using all differentially up-regulated genes 
identified in OIR retinas relative to normoxic retinas at each time point (P14, top; P17, middle; P19, bottom). A 
subset of all enriched GO terms and their fold enrichment are depicted. (e) GO term enrichment analysis in the 
Biological process domain was conducted using all differentially up-regulated genes identified in OIR retinas 
relative to normoxic retinas at each time point (P14, top; P17, middle; P19, bottom). A subset of all enriched GO 
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oxygen levels leading to its reduced expression in embryos in vitro59. Therefore, the reduced expression levels of 
Kcnj8, Mirlet7g, and Sox2 in response to AFL might evidence its beneficial effects on retinal oxygenation, with 
their functional relevance in the OIR retina requiring further investigation. Meanwhile, Gml is speculated to be 
a p53 target involved in the apoptotic pathway and in cell-cycle  regulation60. Yet, its relevance to retinal disease, 
as that of the uncharacterized Pnmal2, remains unknown.
Three genes were up-regulated in both P19 OIR + AFLx2 and P19 OIR + AFLx3 retinas compared to OIR 
controls (Fig. 4c [iii]): 2310008H04Rik (also Spidr), Mir103-1, and Rps19-ps11. The functions of 2310008H04Rik, 
encoding a scaffolding protein involved in DNA repair, in the context of retinal disease are presently unknown. 
Meanwhile, Rps19-ps11 encodes a pseudogene of the ribosomal protein S19 (Rps19). Although pseudogenes are 
presumed to be non-functional as a consequence of mutations and truncation due to premature stop codons, 
some are protein-coding61. In this sense, knockout of Rps19 is pre-implantation lethal in  mice62 and its knock-
down has been shown to result in stagnant blood cells as a consequence of circulatory defects in zebrafish (Danio 
rerio)63. Notably, by binding the macrophage migration inhibitory factor (MIF), Rps19 reduces the adhesion of 
monocytes to  ECs64, which is a key step in the inflammatory response. In turn, miR103-1, whose expression is 
downregulated in RPE cells in response to  hypoxia65, binds the nuclear factor-κB (NFκB) Interacting LncRNA 
(NKILA), whose high levels drive the up-regulation of NFκB, lead to neuronal cell death and protect RPE cells 
from hypoxic  damage66. Hence, the upregulation of these genes at P19 in response to AFL might be relevant for 
the regeneration of the retinal microvascular network, to modulate inflammation, and to protect retinal cells 
from hypoxia.
Interestingly, only one DRG was up-regulated in response to AFL both at P14 and P19 (× 2) (Fig. 4c [iv]), 
namely Hmgcs2, which encodes the ketogenesis rate-limiting enzyme 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 (mHS). HMGCS2 is highly expressed by primary human foetal RPE cells in vitro67 and mHS is one of 
three mitochondrial enzymes often inactivated in  cancer68. Moreover, the product of mHS, β-hydroxybutyrate, 
has a role not only in cellular energetics but also as an agonist of the cell surface receptor GPR109A, a tumour 
suppressor relevant to  apoptosis68. As the metabolic transcriptome of retinal ECs undergoes profound changes 
in pathological  conditions69, the relevance of Hmgcs2 as a possible regulator of EC apoptosis in the OIR retina 
should be addressed in future studies.
Five genes were identified as differentially regulated in response to AFL in three treatment regimens (Fig. 4d). 
At P14, P17 and P19(× 2), AFL significantly down-regulated the expression of Angpt2 (Fig. 4d, [I]), whose lev-
els were also higher in OIR than in normoxia (Fig. 3c). The latter suggests that, by reducing the expression of 
Angpt2 and neutralizing the ligands of VEGFR1 and VEGFR2 simultaneously, AFL might be a more effective 
anti-angiogenic agent than previously recognized. At P17, P19(× 2) and P19(× 3), three genes were differentially 
regulated in response to AFL (Fig. 4d[II]). Encoded by Slc16a14, the monocarboxylate transporter 14 (MCT14) 
has been previously detected in mouse kidneys and  brain70, with its expression recently reported to be confined 
to the endothelial compartment in the central nervous  system71. Notwithstanding, MCT14 remains an orphan 
transporter with unknown functions or substrate  specificities72. Similarly, the role of 2610528A11Rik in the retina 
is currently unknown. However, its human ortholog, chromosome 10 open reading frame 99 (C10ORF99), is 
structurally similar to chemokines of the CC family and modulates the infiltration of T cells to skin transplants 
in  mice73. On this basis, we hypothesize that the upregulation of 2610528A11Rik in response to AFL might be 
relevant to regulate leukocyte recruitment to the OIR retina. Meanwhile, Abcc9, encoding the ATP-binding cas-
sette subfamily C member 9 protein, has been reported as down-regulated in murine OIR  retinas74 and, similar 
to KCNJ8, gain-of-function mutations in ABCC9 have also been reported in Cantú  syndrome75,76. As both Kcnj8 
and Abcc9 encode subunits of ATP-sensitive potassium channels, which have been linked to enhanced retinal 
resistance against severe ischemic  insults77, their AFL-induced down-regulation at P17 and P19 might be a 
consequence of improved retinal oxygenation.
At P14, P17 and P19(× 3), AFL administration led to the reduced expression of Pecam1 (Fig. 4d, [IV]), which 
encodes the platelet endothelial cell adhesion molecule-1 (or CD31). In PECAM-1-deficient mice, retinal vascular 
density is reduced as a consequence of increased EC  apoptosis78. Interestingly, when subjected to the OIR proto-
col, these animals also display reduced retinal neovascularization in spite of VEGF levels being similar to those 
of wild-type control  retinas78. Thus, its down-regulation by AFL might promote apoptosis in neovascular tufts.
Figure 4.  Differential gene expression and GO term enrichment analyses on retinas of OIR + AFL mice relative 
to retinas of non-injected OIR age-matched controls. (a) Differential gene expression analysis on retinas of 
OIR mice that received AFL compared to retinas of OIR age-matched mice that did not at each investigated 
timepoint. A similar impact on the differential regulation of gene expression by AFL is detected after 2 doses 
of AFL at P17 (149 DRGs) and after 3 doses at P19 (151 DRGs). (b) Venn diagram depicting the overlap in 
differentially regulated genes identified at each timepoint in retinas of OIR mice treated with AFL relative 
to retinas of age-matched OIR controls. (× 2) refers to 2 AFL doses and × 3 to 3 AFL doses. (c) Heatmaps 
depicting the fold-change in expression of differentially regulated genes identified in two conditions. The 
specific overlap regions are referenced to the Venn diagram in (b) by the roman numerals i-vi. Note that no 
genes were identified to be differentially regulated in (v), i.e. both at P14 and P19 (× 3). (d) Heatmaps depicting 
the fold-change in expression of differentially regulated genes identified in three conditions. The specific 
overlap regions are referenced to the Venn diagram in (b) by the roman numerals I-IV. Note that no genes were 
identified to be differentially regulated in (III), i.e. both at P14, P19 (× 2) and P19 (× 3). In (II) the fold-change of 
2610528A11Rik is written on the heatmap for the P19 (× 3) time-point. (e) GO term enrichment analysis in the 
Biological process domain was conducted using all differentially regulated genes identified in AFL-treated OIR 
retinas relative to non-treated OIR control retinas at P14 (top) and P17 (bottom). A subset of all enriched GO 
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GO term enrichment analysis using genes differentially regulated in response to AFL revealed the robust mod-
ulatory effects that this agent exerts on angiogenesis even 24 h after the first dose (Fig. 4e, top). Meanwhile, GO 
terms enriched in the biological process domain at P17 (Fig. 4e, bottom) were associated to angiogenesis, smooth 
muscle cell function (e.g. contraction, proliferation), the extracellular matrix (e.g. disassembly, cell–matrix adhe-
sion), response to mechanical stimuli, ion transport (e.g. potassium, chloride), neurotransmission, and synaptic 
maturation. Among the latter, the enriched GO term “chemical synaptic transmission” included the genes Gabra4, 
Tax2, P2rx2, Gabrb1, Glra1, Shc3, Cplx1, Plat, Drd4, and Gabrg3. From these genes, only 2 (Drd4 and Plat) had 
higher expression in OIR than in normoxic retinas, with 7 being lower and one (Tac2) non-significant (Supple-
mentary Fig. S2). Plat encodes a serine protease secreted by endothelial, neuronal, microglial and astrocytic cells 
which is crucial for  fibrinolysis79 and which, in cancer, plays a role in vascular  remodelling80. Thus, its role might 
be more linked to angiogenesis than to synaptic transmission per se. Meanwhile, Drd4 encodes the Dopamine 
receptor D4, whose expression is known to be induced by  hypoxia81 and to reach a peak around P12 in the rat 
 retina82, which correlates with photoreceptor maturation in this species.
Further, it was striking to detect three distinct subunits of the Gamma-aminobutyric acid (GABA) receptor 
Type A  (GABAA) as differentially down-regulated in OIR retinas, with two of them fully and one of them par-
tially restoring their expression levels relative to normoxia in response to AFL.  GABAA receptors are expressed 
in RGCs, where their blockade has been shown to reduce oxidative stress-induced  death83. Whereas this find-
ing by itself could suggest that RGCs engage in a protective behaviour to reduce hypoxia-associated damage 
and death, the reduced expression levels of Glra1, which encodes the subunit alpha-1 of the Glycine receptor 
(also expressed in  RGCs84,85), may instead indicate that RGC functionality and survival is compromised as a 
consequence of OIR and partially rescued by AFL administration. Finally, among the 10 genes associated to 
the chemical synaptic transmission term, P2rx2, which encodes a subunit of a ionotropic receptor expressed in 
starburst amacrine  cells86, was the most significantly down-regulated gene in OIR relative to normoxic retinas 
and subsequently up-regulated in response to AFL at P17. No GO terms in the biological process domain were 
detected as enriched in P19(AFLx2) or P19(AFLx3) retinas. Overall, our findings suggest that, beyond modu-
lating angiogenic processes in the OIR retina while exerting regulatory effects on apoptosis and ion transport, 
AFL also aids in preventing hypoxic damage to retinal neurons, with changes in gene expression suggesting the 
protection of RGCs and amacrine cells.
The genes endogenously modulated by the OIR retina between P17 and P19 overlap only 
marginally with those regulated by AFL at P14 and P17. To investigate whether the transcriptional 
changes undergone by the retina to repair the microvascular aberrations arising as a consequence of the OIR 
protocol overlap with those modulated by AFL, we compared the genes differentially regulated between P17 
and P19 in OIR retinas with those modulated by AFL administration either at P14 or at P17. Of the 1367 DRGs 
identified in OIR from P17 to P19, AFL had an effect on the expression of only 6 of them at P14 and on 16 of 
them at P17, with Igfbp7 being the only gene common to both stages (Fig. 5a). While the elevated expression of 
Igfbps had been reported in other studies on the OIR  model39, it was so far unknown that AFL can maintain the 
expression levels of Igfbp7 in the OIR retina much closer to those observed in normoxic age-matched tissues and 
that this gene is significantly down-regulated during the recovery phase of the OIR protocol (Fig. 5b).
Of the 5 remaining transcripts downregulated both by AFL at P14 and between P17 and P19 in OIR, AFL 
only restored the expression level of one of them, namely BC046401; for the other 4 transcripts, AFL administra-
tion led to an expression level significantly higher than in OIR or normoxia (Fig. 5c). Among these genes, the 
protein encoded by Scara3, Scavenger Receptor Class A Member 3 (also known as Cellular Stress Response Gene 
Protein, CSR), has been shown to protect cells from oxidative stress by scavenging oxidative molecules and harm-
ful products of  oxidation87, while Lymphocyte antigen 6A-2/6E-1 (also known as Stem cells antigen-1, Sca-1), 
encoded by Ly6a, marks a population of multipotent cells in the neonatal murine  retina88 and of bone marrow 
stem cells which differentiate into glial and microglial cells that help preserve visual function in a mouse model of 
retinal ischemia/reperfusion89. Importantly, as Ly6G inhibition was recently reported to impair the endogenous 
capacity of the murine OIR retina to clear neovascular tufts after P17 by depleting it from  neutrophils24, the 
up-regulation of Ly6a we observed in P14 OIR + AFL retinas relative to P14 OIR ones might reflect an increased 
presence of neutrophils with the capacity to promptly destroy such tufts. Thus, these findings suggest that AFL 
may protect the retina from hypoxia-induced damage by increasing the cell’s capacity to tolerate oxidative stress 
while supporting the presence of microglial cells and tuft-clearing neutrophils.
From the 15 genes differentially regulated both in P19 OIR retinas relative to P17 OIR ones and in P17 
OIR + AFL retinas relative to OIR ones at P17 but not at P14, the expression levels of 14 of them were either fully 
(Cd248, Fam188b2, Fam19a4, Kcna4, Mir1896, Pgbd1, RP24-548P4.1) or partially (Cplx1, Hsd17b2, Itgb1, Kcnk9, 
Mcam, Rbm24, Tubb6) restored to normoxic levels by AFL, with only one transcript (Mir467c) maintaining 
expression levels similar to baseline at all timepoints (Fig. 5d). Among these genes, Mcam encodes a vascular wall 
component that plays a prominent role in cancer metastasis and developing tissues by, on the one hand, serving 
as a receptor for multiple pro-angiogenic factors (as Wnt5a, Netrin-1, FGF4, VEGF-C and Wnt1) and, on the 
other, allowing rapidly proliferating cells to migrate more effectively via cell–cell and cell-ECM  interactions90. 
Importantly, CD146 (encoded by Mcam) is a co-receptor required for the phosphorylation of VEGFR-2 upon 
binding with VEGF-A and the subsequent promotion of EC migration and  microvascularization91. Thus, its 
down-regulation by AFL might limit the VEGF-A-induced activation of VEGFR-2 and prevent EC invasion of 
the vitreous body. Meanwhile, Itgb1, which had been briefly discussed earlier, is essential for the formation of 
stable and mature blood vessels but can also impair sprouting angiogenesis in certain  contexts92. Hence, its down-
regulation by AFL might support a more efficient retinal revascularization by promoting sprouting angiogenesis. 
Additionally, the RNA binding motif protein 24 (encoded by Rbm24) is known to post-transcriptionally regulate 
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Figure 5.  Genes differentially expressed both during the post-P17 recovery phase of the OIR protocol and in response to AFL administration 
either at P14 or at P17. (a) Venn diagrams depicting the overlap in differentially regulated genes identified from P17 to P19 in OIR retinas 
and either in P14 (left) or P17 (right) OIR retinas after AFL administration. The two sets of genes overlapping in these comparisons were 
compared to each other, with only one common gene identified (middle). (b–d) Normalized expression levels of the genes identified in the 
overlaps of the Venn diagrams in (a) at each time-point (P14, P17, P19) and condition (Normoxia, OIR, OIR + AFL). The additional P19(× 3) 
time-point refers to retinas of OIR animals that received 3 doses of AFL and were examined at P19. Error bars in (b–d) depict ± 1 S.E.M.
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the stability of the transcription factor  Sox293. As its depletion has been reported to result in anophtalmia or 
microphtalmia in mice and  zebrafish93, which are defects similar to those linked to SOX2 deficiency in humans, 
reduced expression of this gene in OIR retinas might severely impair correct ocular development. In this sense, 
Complexin (encoded by the Cplx1 gene) is relevant for the stabilization and timely release of synaptic  vesicles94 
and its modulation by AFL might be related to improvements in synaptic maturation.
Further, Cd248 is known to be upregulated in response to  hypoxia95 and to encode a marker of tumour vessel-
associated mural cells (Endosialin)96 expressed also on newly forming vessels in developing  tissues97. Therefore, 
its down-regulation in response to AFL at P17 might be the reflection of reduced levels of hypoxia in the tissue. 
Interestingly, the expression trends of Fam19a4 and Kcna4, both of which are known to be expressed in  RGCs98,99, 
change similarly in normoxic and OIR retinas throughout time. The latter suggests that the normalizing effect 
of AFL on the expression of these genes at P17 might be linked to a protective effect on such cell population. 
Meanwhile, the expression dynamics of Mir1896, which is upregulated in activated astrocytes and induces the 
production of inflammatory cytokines and the migration of  CD4+ T cells in a mouse model of experimental 
autoimmune  encephalitis100, suggest that a likely consequence of the hypoxic damage induced to the retina by 
the OIR protocol might be a period of retinal astrocyte activation.
A third dose of AFL normalizes the expression of multiple genes whose levels deviate from 
normoxic ones at P19 in animals that received only two AFL doses. To assess the effect of admin-
istering an additional dose of AFL at P17, we compared the transcriptional profiles of P19 animals subjected to 
the OIR protocol that received two and three AFL injections. This comparison revealed the differential regula-
tion of 92 genes (Supplementary Tables 23–24): 19 up-regulated (Fig. 6a) and 73 down-regulated (Fig. 6b). By 
comparing the expression levels of these 19 up-regulated genes in OIR, OIR + AFL(× 2) and OIR + AFL(× 3) 
retinas against their normoxic levels, we determined that while 9 remained dysregulated in OIR + AFL(× 2) 
tissues, only 3 and 2 were dysregulated in OIR + AFL(× 3) and OIR tissues, respectively (Fig.  6a). Crucially, 
among these 19 genes, the two that remained dysregulated in OIR at P19, namely Vsnl1 and Nabp1, were also 
lower in OIR + AFL(× 2) retinas than in normoxic controls and only a third dose of AFL restored their expres-
sion. While Nabp1 has been primarily linked to the DNA damage response and to transcription termination as 
part of the Integrator  complex101, enriched expression of Vsnl1 has been previously detected in rat RGCs using 
 microarrays102, which suggests that a third dose of AFL prolongs its protective effects on this cell population. 
From the clinical perspective, this finding might be of the utmost relevance in light of the very recently reported 
continuous loss of RGCs in individuals affected by diabetic retinopathy (DR)103.
In contrast, from the 73 genes differentially down-regulated in OIR + AFL(× 3) retinas relative to 
OIR + AFL(× 2) ones, 19 were dysregulated after a third dose of AFL compared to normoxic controls while 
only 13 were differentially expressed in retinas of animals that received only 2 injections. Nonetheless, a third 
dose of AFL effectively normalized the expression levels of 11 of these 13 dysregulated genes, including 3 olfac-
tory receptors (Olfr genes). Indeed, relative to OIR + AFL(× 2) retinas, 17 Olfr genes were down-regulated in 
OIR + AFL(× 3) tissues, which is in agreement with the identification of “sensory perception of smell” and “olfac-
tory receptor activity” as the most and second most enriched GO terms in the biological process and molecular 
function domains, respectively (Fig. 6c). In this context, 96 of the 194 G protein-coupled receptors known to 
be expressed in the retina are putative olfactory  receptors104. However, given the heterogeneous expression pat-
terns of such receptors in the retina, some being specific to certain cell types and others being  ubiquitous105, 
their role in the tissue and the significance of our observations remain to be determined. A third dose of AFL 
also down-regulated the expression levels of 3 and 13 miRNAs compared to P19 normoxic and OIR + AFL(× 2) 
retinas, respectively. Considering the prominent role that microRNAs play during retinal development, as well 
as in pathological  conditions106,107, and the recent report of certain miRNAs gradually changing their expression 
levels throughout the progression from non-proliferative to PDR in  humans103, it is not beyond reason that AFL 
might partially exert its beneficial effects by modulating the expression level of these transcripts. However, this 
hypothesis requires future experimental validation.
Finally, we asked whether a third dose of AFL, compared to a two-dose regimen, could promote the occur-
rence of transcriptional changes characteristic of development. To this aim, we compared the 19 up-regulated and 
73 down-regulated genes in P19 OIR + AFL(× 3) retinas relative to P19 OIR + AFL(× 2) samples with those up and 
down-regulated either from P14 to P17 or from P17 to P19 in the retinas of mice kept in ambient air conditions. 
Our comparison revealed no overlap in down-regulated genes, with one (Stc1) and three (1190002N15Rik, Nabp1, 
Slc7a11) upregulated genes in P19 OIR + AFL(× 3) retinas found to also increase their expression in normoxia 
from P14 to P17 and from P17 to P19, respectively (Fig. 6d). In spite of this limited overlap, the upregulation 
Figure 6.  Differentially expressed genes in P19 OIR + AFL(× 3) relative to P19 OIR + AFL(× 2) retinas, GO 
terms enriched among them, and comparison with differentially regulated genes throughout murine retinal 
development. (a,b) Expression levels of genes differentially up-regulated (a) and down-regulated (b) in P19 
OIR + AFL(× 3) relative to P19 OIR + AFL(× 2) retinas. Expression is shown for P19 OIR, OIR + AFL(× 2) 
and OIR + AFL(× 3) retinas normalized to the expression level detected in normoxic age-matched tissues. (c) 
GO terms enriched in the list of differentially expressed genes in P19 OIR + AFL(× 3) retinas relative to P19 
OIR + AFL(× 2) retinas. Domains: biological process, top; molecular function, middle; cellular component, 
bottom. (d) Venn diagrams of differentially up-regulated (left) and down-regulated (right) genes in P19 
OIR + AFL(× 3) retinas relative to P19 OIR + AFL(× 2) ones and during normal retinal development in the P14 
to P17 period (top) or in the P17 to P19 timeframe (bottom). In (a,b) error bars depict + 1 S.E.M. and statistical 
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of Stc1, which encodes a protein shown to prevent the loss of RGCs in a rat model of optic nerve transection 
in vivo and in RGC-5 cells damaged with  CoCl2 in vitro by reducing oxidative  damage108, and of Slc7a11, which 
encodes an amino acid transport system specific for cysteine and glutamate expressed in  RGCs109, provides 
further evidence of the potential neuroprotective properties of AFL.
Moreover, this marginal overlap in differentially expressed genes suggests that AFL does not promote the 
recapitulation of developmental processes but might instead protect the neuronal retina from hypoxic damage by 
inhibiting the formation of aberrant microvascular structures and supporting the revascularization of the tissue, 
in line with our previous  publication22. In this context, our observations suggest that a regimen with three doses 
of AFL might result in an enhanced neuroprotective effect on RGCs, a cell population that has been described 
as susceptible to damage in diabetes and  DR110.
Discussion
Ischemic retinopathies as DR and ROP exhibit complex morpho-functional phenotypes. Therapeutic strategies 
for their treatment focus primarily on inhibiting the emergence and/or worsening of microvascular aberrations, 
but often fail to directly target the mechanisms giving rise to functional deficits. Moreover, conventional anti-
angiogenic therapies targeting solely VEGF-A are limited by the recurrence of neovascularization, a lack of neu-
ronal functional recovery, their inability to regulate inflammation, and the emergence of drug  resistance3,11,13,111. 
Here, we investigated the retinal transcriptional response to hypoxia and to AFL administration during the 
vaso-proliferative and vaso-regenerative phases of the mouse OIR model.
To examine the transcriptional profile of the OIR retina, recent studies have used bulk and single cell RNA-
sequencing24,112. While these approaches offer the possibility to dissect the heterogeneity of cellular responses 
with high resolution and to identify novel gene isoforms, they often select for polyadenylated transcripts and 
might be limited by sequencing depth. In contrast, microarrays robustly detect both highly and lowly expressed 
genes, non-coding RNAs and predicted  sequences113. On this basis, microarrays have been extensively used to 
study the retinal  transcriptome74,113–116, with us being the first to use them for investigating the response of the 
OIR retina to AFL  administration22. Further, as retinopathy gives rise to complex phenotypic features involving 
and affecting most retinal cell  types3, studying the tissue as a whole might be advantageous to understand the 
pathogenesis of retinal ischemic diseases at the systemic level. The latter, however, is at the expense of a reduced 
capacity to detect subtle changes in transcriptomic profiles within specific cellular populations.
Considering this limitation, we attempted to maximize the sensitivity of our approach by using a low threshold 
for identifying DRGs (fold-change > 1.2). The latter is in line with a recent study on the human diabetic retina 
reporting the magnitude of changes in gene expression levels to be below 50%103. For stringency, we collected 
samples for all conditions in triplicate and utilized a confidence interval of 95% for all comparisons. To validate 
our results, we aimed at comparing them with previously published datasets. However, most studies used dis-
tinct time-points or focused on just a subset of  genes113. Moreover, when comparing with suitable studies, we 
detected divergences potentially arising from thresholding differences, the presence of sex chromosome-linked 
genes (omitted in our study), the use of distinct animal species, and/or modifications to the OIR  protocol19 
(we started hyperoxia one day earlier). For instance, of 662 DRGs we identified at P17 in OIR retinas, only 80 
overlapped with those found by Guarischi-Sousa and colleagues at the same time-point112 (153 in total). In a 
different study, 43 and 1622 DRGs were identified in OIR retinas at P13 and P18,  respectively74; in contrast, we 
detected 272 and 398 DRGs at P14 and P19. Notwithstanding, the processes regulated by the genes we identified 
are consistent with those reported in other studies on the OIR  retina114,117, including sprouting angiogenesis, 
metabolism and inflammation.
Presently, the mechanisms mediating neovascular tuft clearance remain understudied. In a recent report, 
leukocytes were described as central players in this  process24. In agreement, a number of GO terms detected 
as enriched in our study were related to leukocyte migration and chemotaxis. Moreover, the proteins encoded 
by the genes associated to these terms included important regulators of leukocyte adhesion and transendothe-
lial migration, as well as modulators of monocyte infiltration and neutrophil migration. Additionally, as high 
VEGF-A levels have been suggested to lead to leukostasis in the  eye118, its neutralization by AFL might expedite 
leukocyte recruitment to neovascular tufts for their subsequent clearance. In this context, our findings are in line 
with previous reports and hint at the potential regulatory role of AFL on this process.
The number of DRGs detected in response to two doses of AFL at P17 (149) was similar to that observed at 
P19 after three doses (151). Interestingly, however, no single gene was differentially regulated in all treatment 
regimens. Yet, the most relevant target of AFL identified in our study might be Angpt2, as its expression was con-
sistently elevated at all examined time points in OIR retinas, in agreement with a previous  report119, and down-
regulated by AFL at P14, P17 and P19 after 2 doses; in P19(× 3) retinas its fold-change was -1.16 (P value = 0.09). 
Ang2 is an antagonist of the tyrosine kinase receptor Tie2 whose importance in vascular development is difficult 
to overstate. While the expression of Ang2 is responsive to  hypoxia120 and its dysregulation is characteristic of 
 disease121, its blockade has been shown to reduce tumour vascularization and to inhibit metastasis in mammary 
gland carcinomas and pancreatic  insulinomas122. Additionally, Ang2 has been implicated in  OIR123 and described 
to be up-regulated in the serum of type 2 diabetic patients with either non-proliferative DR or PDR compared 
to patients without  retinopathy124. These findings have attracted interest in the possibility of pharmacologically 
regulating the activity of this agent, with clinical trials assessing the efficacy of neutralizing this molecule cur-
rently  ongoing125. In this sense, the bispecific anti-VEGF/anti-Ang2 antibody Faricimab has been shown to be 
more effective than sole anti-VEGF therapy in an animal model of laser-induced choroidal  neovascularization126 
and studies evaluating the therapeutic efficacy of simultaneously blocking VEGF-A and Ang2 are  ongoing127. As 
Angpt2 expression is increased in response to stabilization of the hypoxia-inducible  factor2, our results suggest 
that AFL is effective in reducing retinal hypoxia.
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Two more genes prominently involved in angiogenesis and modulated by AFL were Esm1 and Cd34. Esm1 has 
been previously reported as a top overexpressed gene in OIR retinas at  P17113,119 and plays a role in both patholog-
ical and physiological angiogenesis, modulating VEGF bioavailability and regulating leukocyte  extravasation128. 
Moreover, increased expression of Esm1 enhances the proliferative capacity, colony forming ability, migration 
and invasiveness of radiotherapy-resistant breast cancer cells all by itself, with its down-regulation reversing these 
 effects129. Meanwhile, Cd34 has been previously shown to promote pathological neovascularization in the OIR 
 retina130. Therefore, the downregulation of these genes might constitute a relevant mechanism by which AFL 
inhibits the formation of neovascular tufts while promoting their clearance and permitting the regeneration of 
the retinal microvascular network. Together, our observations suggest that the capacity of AFL to concomitantly 
modulate the synthesis and deposition of ECM components, which regulate adhesion, together with its effects on 
Angpt2 levels, might represent key mechanisms by which it orchestrates a more efficient recovery of the retinal 
microvasculature. Specifically, we hypothesize that lower levels of Ang2 are central to supress the exuberant 
vasoproliferation characteristic of the OIR retina while the normalization in the composition of the basement 
membrane might allow ECs to migrate and assemble functional vessels that contribute to reducing tissue hypoxia 
more effectively. Moreover, besides genes, we reveal that AFL exerts regulatory effects over certain miRNAs. 
Given the broad spectrum of binding partners of each individual miRNA species, their ease of synthesis and 
their limited toxicity, these small RNAs might be valuable not just as disease biomarkers but also as powerful 
therapeutic agents and targets.
Beyond its marked regulatory effects on angiogenesis, AFL also modulated inflammatory processes and 
exhibited neuroprotective features, as revealed by the enrichment of GO terms associated to wound healing and 
synaptic transmission. Moreover, considering that ion flux into photoreceptors is a critical process for vision often 
disrupted in  diabetes3, the enrichment of GO terms associated to potassium, calcium, and chloride ion transport 
in response to AFL administration provides further evidence of its beneficial effects on visual perception, in line 
with our previous  findings22. The latter is of key relevance as damage to retinal neurons can be detected before 
vascular abnormalities in human patients with  diabetes127. Modulating not only angiogenesis but also a broader 
spectrum of processes relevant to retinal function and apparently protecting not only dopaminergic amacrine 
cells from hypoxic damage, as we have previously  reported22, but potentially also RGCs, AFL might be a more 
powerful agent than previously recognized. In this sense, our exploratory study might serve as a valuable resource 
for informing future research aimed at the identification of additional molecular targets whose pharmacological 
regulation might be beneficial for the treatment of multiple retinopathies, including diabetic retinopathy and 
retinopathy of prematurity.
Methods
Study approval. Animal experiments were performed in strict accordance with German Animal Welfare 
legislation and adhering to the ARRIVE guidelines. All experimental protocols (TVV26/2017) were reviewed 
and approved by the Landesdirektion Dresden with the approval number DD24.1‐5131/394/29. All efforts were 
made to minimize animal suffering. Anesthesia overdosing prior to eye collection was verified by the absence 
of interdigital withdrawal reflexes. Pharmacological euthanasia was followed by decapitation. All mice were 
acquired from Charles River Laboratories (Sulzfeld, Germany), either to breed in‐house or as pregnant females. 
Newborns were allocated to experimental groups arbitrarily and irrespective of their sex.
OIR protocol and Aflibercept administration. Retinal neovascularization was induced by the OIR 
 protocol19. The protocol consisted in exposing C57BL/6J (IMSR Cat# JAX:000664, RRID:IMSR_JAX:000664) 
mouse pups and their mothers to 75% oxygen from P6 to P11 (P0 = birthdate); before and afterwards, all mice 
were housed in ambient air conditions in cages with wood shavings beddings and using a 12 h light/dark cycle. 
Temperature control and water quality was continuously monitored and followed the regulations of the TU 
Dresden Medical Faculty Animal House. Aflibercept (Bayer Vital GmbH, Leverkusen, Germany) diluted in ster-
ile PBS (Sigma‐Aldrich, Munich, Germany) was administered intra‐peritoneally to half the pups in each litter 
at 25 mg/kg BW on one of two regimens: either on P13 and P15 or on P13, P15 and P17. Non-injected OIR 
littermates were kept as controls. Half the animals in each litter were arbitrarily allocated by the experimenter 
to the Aflibercept‐treated group and the remaining half to the non‐injected OIR control group. No exclusion 
criteria were enforced and all animals were considered. In total, 12 mice were used in the present study. Non-
OIR animals (normoxic controls) were reared in ambient air conditions. Normoxic controls were not injected 
with any substance before being sacrificed. All mice were sacrificed between 13:00 and 17:00 h (CET + 1) by an 
overdose of ketamine (300 mg/kg BW; Ratiopharm, Ulm, Germany) and xylazine (30 mg/kg BW; Ratiopharm). 
The effectiveness of the OIR protocol was ascertained by confirming the presence of neovascularization and 
vaso-obliteration by immunofluorescence in flat-mounts of retinas from animals used for a different study which 
were inside the hyperoxia chamber at the same time-points as the animals used for this study. The oxygen con-
centration in the hyperoxia chamber was monitored daily to confirm deviations did not exceed ± 2%, which from 
previous experience is considered an acceptable range.
RNA isolation. Three P19 mice per condition (normoxia, OIR, OIR + AFLx2, OIR + AFLx3) were used for 
RNA isolation. The retinas of each mouse were dissected in PBS at 37 °C and subsequently pooled together. 
Warm PBS was replaced by 750 µL TRIzol (Thermo Fisher Scientific), and retinal tissues were disrupted by 10 
rounds of aspiration/ejection through 18G needles and 10 more rounds through 23G needles. After 5 min incu-
bation at room temperature, 150 µL chloroform (Merck, Darmstadt, Hesse, Germany) were added and samples 
were vortexed, incubated an additional 15 min at RT, and centrifuged 20 min at 12,000g and 4 °C. The aqueous 
phase was subsequently collected and mixed with 1.5 µl RNA‐grade glycogen (Thermo Fisher Scientific) and 
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375 µl isopropanol (Merck). Samples were subsequently vortexed and centrifuged 20 min at 12,000g and 4 °C. 
Pellets were washed twice in 1 ml 75% ethanol, air‐dried 10–20 min, and re‐suspended in 20 µL RNAse‐free 
water. Aliquots of 1 µL RNA per sample were kept separate for quality control measurements avoiding unneces-
sary freeze–thaw cycles.
Gene expression profiling, GO Term and KEGG pathway enrichment analysis. Isolated RNA was 
sent to the Gene Expression Facility of the Max Planck Institute for Cell Biology and Genetics (Dresden, Saxony, 
Germany). There, biotinylated cDNA samples were prepared according to the GeneChip WT PLUS Reagent Kit 
(Cat. Nr. 902280) protocol using 250 ng total RNA as starting material. 5.5 ug of biotinylated and fragmented 
single-stranded cDNA were hybridized for 16 h at 45 °C on Affymetrix GeneChip Mouse Whole Transcriptome 
Arrays according to the GeneChip® WT PLUS Reagent Kit User Manual. GeneChips were washed and stained in 
the Affymetrix Fluidics Station 400. GeneChips were subsequently scanned using the Hewlett-Packard GeneAr-
ray Scanner G2500A. Scanned images were processed with the Transcriptome Analysis Console (TAC) Software 
(Affymetrix) using default parameters to obtain background subtracted and summarized probe sets. Data (.CEL 
files) generated in these microarray chips was imported into GeneSpring v14.9 (Agilent Technologies) together 
with the .CEL files generated in our previous study (GEO accession number: GSE124956) describing the response 
of the OIR retina to AFL administration at earlier time-points, namely P14 and P17. By normalizing all datasets 
together using the Robust Multi-array Average (RMA) approach, we aimed at ensuring comparability across all 
datasets. No baseline transformation was conducted. Normalized expression levels were used to identify dif-
ferentially regulated genes in GeneSpring. A gene was considered to be differentially expressed if it exhibited 
a fold-change above or below 1.2 and a p-value below 0.05 as a result of pairwise comparison (unpaired t test) 
across time-points or conditions. False discovery rate (FDR) was not used. Transcripts expressed from the X or Y 
chromosome were not considered for analysis. Data were exported as .csv files for further analysis. The microar-
ray data produced in this study has been deposited in the NCBI Gene Expression Omnibus database (accession 
number GSE137705). Venn diagrams were created using  InteractiVenn131 and refined in Adobe Illustrator. Lists 
of differentially regulated genes were used as input in  PANTHER25–27 and  ShinyGO132 for identifying enriched 
GO terms and KEGG Pathways, respectively. PANTHER settings were used as default, i.e. using a Fisher’s Exact 
test and a False Discovery Rate correction. When a high number of terms or pathways were detected, a subset of 
the most specific terms was arbitrarily selected and used for depiction in figures.
Data availability
The microarray data produced in this study, including raw files (.CEL) and an expression matrix with absolute 
and normalized intensity values for each entity detected, have been deposited in the NCBI Gene Expression 
Omnibus database (accession number GSE137705). All data from our previous study describing the response 
of the OIR retina to AFL administration at earlier time-points, namely P14 and P17, has also been deposited in 
the NCBI Gene Expression Omnibus and is publicly available (GEO accession number: GSE124956). Differential 
gene expression data generated for this research article is included as Supplementary Information.
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